Latest News (EN)
Daraxonrasib doubles median survival in metastatic pancreatic cancer
Daraxonrasib, an investigational oral inhibitor of the RAS oncogene, doubled the median survival of patients with metastatic pancreatic adenocarcinoma. The drug was...
